Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Nexalin Technology Inc WT (NXLIW)

Nexalin Technology Inc WT (NXLIW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents GlobeNewswire - Thu Apr 9, 6:47AM CDT

BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further supporting Nexalin’s differentiated, non-invasive...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)
Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market GlobeNewswire - Tue Feb 24, 7:07AM CST

150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment Builds on Prior Peer-Reviewed...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders GlobeNewswire - Mon Feb 23, 7:18AM CST

HOUSTON, TX, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), developer of Deep Intracranial Frequency Stimulation (DIFS™) technology...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care GlobeNewswire - Thu Feb 5, 7:37AM CST

HOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)
Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation GlobeNewswire - Mon Feb 2, 7:45AM CST

HOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)
Nexalin Technology Receives Nasdaq Listing Status Notification GlobeNewswire - Fri Jan 23, 4:15PM CST

HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)
Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD GlobeNewswire - Wed Jan 14, 8:00AM CST

HOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™)...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program GlobeNewswire - Wed Dec 3, 2025

HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4 GlobeNewswire - Tue Dec 2, 2025

HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)
Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity GlobeNewswire - Tue Nov 18, 2025

HOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain,...

NXL : 0.3800 (+8.57%)
NXLIW : 0.0138 (-9.21%)

Barchart Exclusives

Up 24% in 2026 and Yielding 3.1%, How Should You Play SHEL Stock Amid an Iran Ceasefire? Barchart - Thu Apr 9, 6:30PM CDT
Shell is riding a rare combination of surging oil prices, strong trading gains, and a 25% year‑to‑date stock rally that has pushed SHEL to its best run in years, even as the Iran conflict forces the company to trim its gas output outlook and watch the Strait of Hormuz closely. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.